CagriSema: The Amylin + GLP-1 Combination — Mechanism, Trial Results & FDA Timeline

The Short Answer

CagriSema is Novo Nordisk's next-generation obesity treatment combining two proven mechanisms — a long-acting amylin analogue (cagrilintide 2.4 mg) and a GLP-1 receptor agonist (semaglutide 2.4 mg) — in a single once-weekly injection.

Phase 3 trials show 22.7% average weight loss at 68 weeks in adults with obesity (REDEFINE 1) and 15.7% weight loss in adults with type 2 diabetes (REDEFINE 2). Novo Nordisk filed the NDA with the FDA in December 2025, with approval expected in late 2026 or early 2027.

CagriSema is the first combination therapy to target both amylin and GLP-1 pathways simultaneously, potentially offering superior weight loss over either component alone.

What Is CagriSema?

If semaglutide (Wegovy) was the opening act of the modern weight-loss drug revolution, CagriSema is designed to be the headliner. Developed by Novo Nordisk — the same company behind semaglutide and Wegovy — CagriSema pairs two distinct hormonal pathways into one weekly shot.

The name itself is a mashup: Cagri (from cagrilintide, the amylin component) + Sema (from semaglutide, the GLP-1 component). Each addresses appetite and metabolism through different but complementary mechanisms, producing effects that neither drug achieves alone.

Here's the critical distinction: while tirzepatide (Mounjaro/Zepbound) combines GIP and GLP-1 signaling, CagriSema combines amylin and GLP-1 signaling. These are fundamentally different biological strategies for the same goal — and CagriSema's dual-pathway approach may unlock weight loss plateaus that single-mechanism drugs hit.

How CagriSema Works: The Dual-Pathway Mechanism

CagriSema's two active ingredients target appetite and metabolism through distinct neural and hormonal pathways.

The Amylin Pathway (Cagrilintide)

Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells after meals. Natural amylin levels are often disrupted in obesity and type 2 diabetes. Cagrilintide is a long-acting synthetic analogue that restores and amplifies this signaling.

What the amylin pathway does:

• ●Activates the area postrema — a brain region outside the blood-brain barrier that directly senses circulating hormones and modulates satiety signals
• ●Slows gastric emptying through vagal nerve signaling, extending the feeling of fullness after meals
• ●Suppresses glucagon secretion, reducing the liver's glucose output between meals
• ●Creates independent satiety that stacks on top of GLP-1-mediated appetite suppression

The GLP-1 Pathway (Semaglutide)

Semaglutide 2.4 mg — the same dose used in Wegovy — is the most extensively studied GLP-1 receptor agonist in obesity. It works through well-established mechanisms:

• ●Activates hypothalamic appetite centers, reducing hunger and food cravings at the neurological level
• ●Enhances insulin secretion in a glucose-dependent manner, improving blood sugar regulation
• ●Slows gastric emptying through a parallel but distinct mechanism from amylin
• ●Reduces reward-driven eating by modulating dopaminergic pathways in the brain

Why the Combination Matters

The key insight behind CagriSema is that amylin and GLP-1 pathways converge on different nodes of the appetite-regulation network. When activated simultaneously, they create a more comprehensive suppression of hunger than either pathway alone.

Think of it this way: GLP-1 primarily works through the hypothalamus (the brain's appetite "thermostat"), while amylin works significantly through the area postrema and brainstem (the brain's "satiety checkpoint"). By engaging both control centers, CagriSema produces what researchers call additive or supra-additive appetite suppression.

This biological redundancy also means that if one pathway experiences tachyphylaxis (reduced sensitivity over time), the other pathway continues working — potentially addressing the weight loss plateaus that many patients experience on GLP-1 monotherapy.

Clinical Trial Results: The REDEFINE Program

Novo Nordisk's Phase 3 clinical program for CagriSema — called REDEFINE — includes multiple trials across different patient populations.

REDEFINE 1: Adults with Obesity (Without Diabetes)

The headline trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) without type 2 diabetes.

Key results at 68 weeks:

The most striking finding: CagriSema produced 22.7% weight loss versus 16.1% for semaglutide alone — a 6.6 percentage point improvement over the exact same GLP-1 dose. This demonstrates that adding the amylin pathway provides substantial additional efficacy beyond what GLP-1 alone can achieve.

However, the 22.7% result landed slightly below Novo Nordisk's internal expectations of ≥25%, which caused a temporary dip in the company's stock price. Context matters here — 22.7% is still one of the highest weight loss figures ever recorded in a Phase 3 obesity trial.

REDEFINE 2: Adults with Type 2 Diabetes and Obesity

This trial focused on a harder-to-treat population — adults with both type 2 diabetes and obesity/overweight.

Key results at 68 weeks:

Patients with type 2 diabetes consistently show lower absolute weight loss percentages across all GLP-1 and combination therapies — this is a well-established pattern. The 15.7% result in this population is clinically meaningful and demonstrates CagriSema's efficacy even in metabolically complex patients.

REDEFINE 3: Cardiovascular Outcomes (Ongoing)

This major outcomes trial has enrolled approximately 7,000 participants with established cardiovascular disease and obesity, evaluating whether CagriSema reduces 3-point MACE (major adverse cardiovascular events). Results are expected in 2027-2028.

REDEFINE 4: Head-to-Head vs. Tirzepatide (Ongoing)

Perhaps the most anticipated trial in the entire program — a direct comparison of CagriSema against tirzepatide 15 mg (Zepbound). With 800 participants and a 72-week endpoint, this will provide the first head-to-head data between Novo Nordisk's and Eli Lilly's next-generation platforms. Results are expected in 2026-2027.

Side Effect Profile

CagriSema's side effect profile is consistent with what's seen across the GLP-1 agonist class, with gastrointestinal symptoms being most common.

Common Side Effects

• ●Nausea — Most frequently reported, typically peaks during dose titration and subsides within 4-8 weeks
• ●Diarrhea — Occurs in approximately 20-30% of patients
• ●Vomiting — More common during the initial titration period
• ●Constipation — Affects some patients as gastric emptying slows
• ●Injection site reactions — Mild, localized, and typically resolve quickly

Important Considerations

Because CagriSema contains semaglutide 2.4 mg — the full Wegovy dose — its GI side effect profile is comparable to Wegovy. The addition of cagrilintide doesn't appear to dramatically worsen tolerability, which is encouraging given the enhanced efficacy.

Patients who have already tolerated semaglutide may find CagriSema's side effects manageable, while those new to incretin therapy should expect the standard titration-period adjustment.

CagriSema vs. Other Weight Loss Medications

How does CagriSema stack up against the current and emerging competition?

Who Might Benefit from CagriSema?

CagriSema occupies a specific niche in the emerging weight-loss pharmacology landscape:

Strongest candidates:

• ●Adults who've plateaued on semaglutide (Wegovy) monotherapy and need additional weight loss
• ●Patients with BMI ≥35 where maximal initial weight loss is clinically important
• ●Adults with type 2 diabetes and obesity seeking dual metabolic benefits
• ●Patients who respond well to GLP-1 therapy but haven't reached their weight-loss goals

Less ideal candidates:

• ●Patients who haven't tried GLP-1 therapy yet (starting with semaglutide monotherapy is standard practice)
• ●Those with a history of severe GI intolerance to GLP-1 medications
• ●Patients with medullary thyroid carcinoma or MEN 2 syndrome

Regulatory Timeline and Availability

The path to market for CagriSema follows a predictable regulatory trajectory:

• ●December 2025: NDA submitted to FDA for obesity indication
• ●2026: FDA review period (standard 10-12 month review)
• ●Late 2026 / Early 2027: Expected FDA approval decision
• ●2027: Anticipated U.S. market launch
• ●2026-2027: Submissions expected for type 2 diabetes indication based on REIMAGINE trial data

Cost Expectations

Pricing hasn't been officially announced, but market analysts expect CagriSema to be priced at a premium to Wegovy, given its combination mechanism and superior efficacy data. Current Wegovy list pricing (~$1,350/month) provides a reference point, though actual patient costs will depend heavily on insurance coverage and Novo Nordisk's pricing strategy.

The evolving competitive landscape — particularly orforglipron's projected pricing starting at $149/month — will likely influence CagriSema's market positioning.

The Bottom Line

CagriSema represents Novo Nordisk's strongest answer to the competitive pressure from Eli Lilly's tirzepatide and retatrutide. By combining two biologically distinct appetite-suppression pathways, it achieves weight loss that surpasses either component alone.

The 22.7% weight loss in REDEFINE 1 places CagriSema squarely in the top tier of obesity treatments, though head-to-head data against tirzepatide (REDEFINE 4) will ultimately determine where it ranks. For patients who've already benefited from semaglutide but want more, CagriSema may become the natural next step.

With the NDA filed and FDA review underway, CagriSema is on track to reach patients by 2027 — further expanding the options available in what's becoming the most competitive era in obesity pharmacotherapy.

Frequently Asked Questions

How is CagriSema different from Wegovy?

Both contain semaglutide 2.4 mg, but CagriSema adds cagrilintide — a long-acting amylin analogue that suppresses appetite through a separate brain pathway. This combination produced 22.7% weight loss versus approximately 15-17% with semaglutide alone.

When will CagriSema be available?

Novo Nordisk filed the NDA with the FDA in December 2025. Approval is expected in late 2026 or early 2027, with a U.S. market launch anticipated in 2027.

Is CagriSema better than Zepbound (tirzepatide)?

Phase 3 data suggests comparable weight loss (~22.7% for CagriSema vs. ~22-26% for tirzepatide), but head-to-head results from REDEFINE 4 are expected in 2026-2027 and will provide a definitive comparison.

What are the main side effects?

Gastrointestinal symptoms are most common — nausea, diarrhea, vomiting, and constipation. These are consistent with the GLP-1 agonist class and typically improve after the initial titration period.

Will insurance cover CagriSema?

Coverage will depend on individual insurance plans and payer decisions. Obesity treatment coverage has expanded significantly since semaglutide's approval, and the trend is expected to continue as clinical evidence for weight loss medications grows.

References

1. ●Novo Nordisk. "Novo Nordisk files for FDA approval of CagriSema." Press Release, December 18, 2025.
2. ●REDEFINE 1 Trial Results. Presented at ObesityWeek 2024.
3. ●REDEFINE 2 Trial Results. Presented at ADA Scientific Sessions 2025.
4. ●Frias JP, et al. "Cagrilintide plus semaglutide for obesity." The New England Journal of Medicine. 2024.
5. ●Novo Nordisk REDEFINE Clinical Trial Program Overview. ClinicalTrials.gov.

This article is for informational and educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. PeptideIQ does not endorse or promote the use of any specific drug or treatment.

Last updated: February 2026